Interestingly, retrospective cohort studies found that men exposed to the mineralocorticoid receptor (MR)-antagonist spironolactone had a lower PCa risk [59,60], suggesting the tumor-promoting role of the MR. The gene discussed is NR3C2; the disease is posterior cortical atrophy.